Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.41 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.41 |
| ▸ | PNLIP | P16233 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19145089 | 0.88 | ARG1 (0.52) | ARG1APPTRPA1MAPTCYP1A2 | |
| SCHEMBL9484979 | 0.85 | ABL1 (0.55) | ARG1APPMAPTHSD17B10PNLIP | |
| SCHEMBL11990845 | 0.84 | ALDH1A1 (0.56) | ARG1IDO1APPMAPTCYP1A2 | |
| SCHEMBL29642426 | 0.83 | ARG1 (0.59) | ARG1IDO1TRPA1MAPTTP53 | |
| SCHEMBL347616 | 0.83 | ARG1 (0.59) | ARG1IDO1TRPA1MAPTTP53 | |
| SCHEMBL14756802 | 0.82 | MAPT (0.53) | ARG1TRPA1MAPTTP53CYP1A2 | |
| Hydrochloric Acid SCHEMBL1825913 | 0.81 | ARG1 (0.57) | ARG1IDO1TRPA1MAPTINSR | |
| SCHEMBL5547526 | 0.81 | ARG1 (0.57) | ARG1APPMAPTTP53CYP1A2 | |
| SCHEMBL15934274 | 0.80 | TUBB4A (0.57) | APPTP53CYP1A2ALOX15TSHR | |
| SCHEMBL11256391 | 0.79 | ARG1 (0.55) | ARG1IDO1MAPTTP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103468031-B | Nano/microparticle ionic material and preparation method thereof | NINGBO HAITENG NEW MATERIALS CO LTD | 2014-11-26 | — | — | CN | disclosed |
| CN-103468031-A | Nano/microparticle ionic material and preparation method thereof | NINGBO HAITENG NEW MATERIALS CO LTD | 2013-12-25 | — | — | CN | disclosed |
| US-7569676-B2 | Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1498415-B1 | Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs | ROCHE DIAGNOSTICS GMBH (DE) | 2007-06-27 | — | — | EP | disclosed |
| US-7060847-B2 | Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20050153439-A1 | Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs | GHOSHAL MITALI (US) | 2005-07-14 | — | — | US | disclosed |
| US-20050014210-A1 | Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs | ROCHE DIAGNOSTICS CORPORATION | 2005-01-20 | — | — | US | disclosed |
| EP-1498415-A1 | Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs | Roche Diagnostics GmbH (DE) | 2005-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014210-A1 | Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs | DRD3, SLC6A3, DRD2 | ARG1 4792/4885IDO1 441/4885APP 2327/4885 |
| US-20050153439-A1 | Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs | DRD3, SLC6A3, DRD2 | ARG1 4792/4885IDO1 441/4885APP 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.